Date Source Title Access 1 5 May 2019 Hitanshu Dhingra, Adelaide Equity & Partners Ltd A deep dive into Paradigm's OA program and partnering prospects Download PDF 2 23 Jan 2019 Marc Sinatra, Lodge Partners Paradigm Biopharmaceuticals: Mucoplysaccharidosis and what’s to come going forward: BUY Download PDF 3 Nov 25 2018 Fiftyone Capital The Next Australian Blockbuster Biotech Access link 4 5 June 2018 Fiftyone Capital Paradigm Biopharmaceuticals Ltd Research Access link
research reports and media, page-2
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
28.0¢ |
Change
-0.005(1.75%) |
Mkt cap ! $97.94M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 29.0¢ | 27.5¢ | $83.90K | 296.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 34310 | 28.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 126570 | 4 |
View Market Depth
| Last trade - 16.10pm 16/05/2024 (20 minute delay) ? |
|
|||||
|
Last
28.0¢ |
Change
-0.005 ( 1.23 %) |
||||
| Open | High | Low | Volume | ||
| 28.0¢ | 29.0¢ | 27.5¢ | 130724 | ||
| Last updated 15.52pm 16/05/2024 ? | |||||
| PAR (ASX) Chart |